Clinical Research Directory
Browse clinical research sites, groups, and studies.
WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial
Sponsor: University of Washington
Summary
This phase II trial tests how well the WOKVAC vaccine works in preventing brain metastases in patients with HER2 positive, hormone receptor negative or low breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). WOKVAC is a vaccine made from tumor-associated proteins, pUMVC3, IGFBP2, HER2, and IGF1R, and may help the body build an effective immune response to kill tumor cells. Sargramostim is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets It is a cytokine that is a type of hematopoietic (blood forming) agent. Giving WOKVAC mixed with sargramostim may help prevent the development of brain metastases in patients with HER2 positive, hormone receptor negative or metastatic breast cancer.
Official title: A Single-Arm, Phase II Trial: Study of HER2+ Metastatic Breast Cancer Immunization to Enable CNS Lesion Defense (SHIELD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2026-11-30
Completion Date
2035-12-31
Last Updated
2026-11-19
Healthy Volunteers
No
Conditions
Interventions
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Given ID
Computed Tomography
Undergo CT
Magnetic Resonance Imaging
Undergo MRI
Sargramostim
Given ID
Tetanus and Diphtheria Toxoids Adsorbed
Given tetanus-diptheria immunization
Biospecimen Collection
Undergo blood sample collection
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States